Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Eli Lilly announced results of Jaypirca
    15 April 2026

    Eli Lilly announced results of Jaypirca (pirtobrutinib)

    Eli Lilly and Company announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy until their disease progresses. 

  • 15 April 2026
    Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

    Johnson & Johnson today announced favorable 12-month interim effectiveness and safety results from VARIPURE, the largest prospective post-market follow-up study evaluating first-time pulsed field ablation (PFA) using the VARIPULSE Platform. The data were presented at the PFA Summit during the 2026 European Heart Rhythm Association (EHRA) Annual Meeting in Paris and simultaneously published in Europace.

  • 13 April 2026
    Connect, Present, and Inspire for Students, Research Scholars, and Academicians

    The Department of Pharmacy Practice, SIMATS College of Pharmacy, Chennai, in collaboration with the Indian Pharmaceutical Association (IPA) and IPA Tamil Nadu State Branch, successfully conducted a Five-Day Virtual Poster Showcase (VPS 2026) from April 6–10, 2026. The event, held via Google Meet, aimed to promote research aptitude and scientific communication among students and early-career academicians.

  • 10 April 2026
    Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA
    Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.
  • 10 April 2026
    Amgen announced results from a Phase 3 trial of TEPEZZA
    Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease
  • 8 April 2026
    FDA approves First Generic Dapagliflozin Tablets
    U.S. Food and Drug Administration approved the first generics of FARXIGA (dapagliflozin) tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • 3 April 2026
    Imfinzi plus Imjudo combined with lenvatinib and transarterial chemoembolisation improves survival in liver cancer

    Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone for patients with unresectable hepatocellular carcinoma (HCC) eligible for embolisation.

  • 2 April 2026
    DCC refers retail pharmacy deregulation proposals to sub-committee, including removal of pharmacist name from licence

    In a significant step toward easing the regulatory burden on India's retail pharmacy sector, the Drugs Consultative Committee (DCC) at its 68th meeting on 20 March 2026 directed a sub-committee to examine four landmark deregulation proposals. The sub-committee's findings will be placed before the DCC for final deliberation before any rule amendments are made.

  • 2 April 2026
    Lilly's novel weight loss medicine gets FDA approval

    Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems.

    When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

  • 30 March 2026
    New Drug Shows 91% Reduction in Seizures in Children with Rare Epilepsy

    A groundbreaking investigational therapy is offering new hope for children affected by Dravet syndrome, a severe and treatment-resistant form of epilepsy. The drug, known as zorevunersen, has demonstrated remarkable results in clinical trials, significantly reducing seizure frequency while also improving cognitive and behavioral outcomes.

Subscribe to Pharma News